Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Alzheimer's symbols : LLY save search
Roche granted FDA Breakthrough Device Designation for blood test to support earlier Alzheimer's disease diagnosis
Published: 2024-04-11 (Crawled : 05:00) - globenewswire.com
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
|
| O: 1.06%
H: 0.47%
C: -0.03%
fda device disease test granted blood designation for alzheimer's roche
Insights Into the Global Alzheimer's Disease Market, 2023-2032 - Eli Lilly's Donanemab Poised as Front-Runner for 2024 Market Debut, Set to Rival Biogen and Eisai's LEQEMBI in Emerging Therapy Arena
Published: 2023-08-18 (Crawled : 19:00) - prnewswire.com
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
| Email alert
Add to watchlist
leqembi disease global alzheimer's set therapy market
ALZHEIMER'S ASSOCIATION STATEMENT ON DONANEMAB PHASE 3 DATA REPORTED AT AAIC 2023
Published: 2023-07-17 (Crawled : 14:20) - biospace.com/
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
|
| O: -0.0%
H: 0.26%
C: -0.51%
association alzheimer's aaic
Lilly Announces Webcast to Provide Alzheimer's Disease Update at AAIC
Published: 2023-07-11 (Crawled : 18:00) - biospace.com/
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
|
| O: -0.7%
H: 0.12%
C: -2.36%
disease update alzheimer's aaic
Lilly's Donanemab Significantly Slowed Cognitive and Functional Decline in Phase 3 Study of Early Alzheimer's Disease
Published: 2023-05-03 (Crawled : 10:00) - prnewswire.com
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
|
| O: 2.68%
H: 4.62%
C: 3.89%
disease alzheimer's study
Roche announces collaboration with Lilly to enhance early diagnosis of Alzheimer's disease
Published: 2023-03-22 (Crawled : 07:00) - globenewswire.com
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
|
| O: 0.21%
H: 1.15%
C: -0.24%
disease alzheimer's collaboration roche
Lilly Provides Update on A4 Study of Solanezumab for Preclinical Alzheimer's Disease
Published: 2023-03-08 (Crawled : 23:00) - prnewswire.com
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
|
| O: -0.07%
H: 2.07%
C: 1.45%
disease preclinical alzheimer's update study
Insights on the Alzheimer's Drugs Global Market to 2027 - Hospital Sector will Capture more Revenue in Upcoming Years
Published: 2023-01-25 (Crawled : 21:00) - prnewswire.com
SNYNF | News | $94.25 -2.18% 480
|
Health Technology
|
| O: -0.96%
H: 0.0%
C: 0.0%
NVSEF | News | $96.0 6.88% 52K
|
Health Technology
|
| O: -1.1%
H: 0.0%
C: 0.0%
PFE | News 4 | $26.27 -0.19% -0.15% 23M
|
Health Technology
|
| O: -1.93%
H: 0.23%
C: 0.11%
NVS | News | $98.35 1.1% 0.0% 2.2M
|
Health Technology
|
| O: -1.97%
H: 0.11%
C: -1.25%
GSK | News | $40.86 -0.92% -0.15% 1.7M
|
Health Technology
|
| O: 0.4%
H: 0.28%
C: 0.08%
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
|
| O: 0.36%
H: 0.34%
C: -0.85%
ABT | News | $106.89 -0.65% -0.22% 5.1M
|
Health Technology
|
| O: 0.23%
H: 0.33%
C: -0.16%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: 0.89%
H: 0.0%
C: 0.0%
global alzheimer's market
Lilly Shares Positive Donanemab Data in First Active Comparator Study in Early Symptomatic Alzheimer's Disease
Published: 2022-11-30 (Crawled : 00:00) - prnewswire.com
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
|
| O: 1.0%
H: 0.11%
C: -1.19%
disease active alzheimer's positive study
Global Alzheimer's Therapeutics Market Report 2022-2030 - Incidence and Cost Burden of Dementia Associated with AD is Expected to Boost Market Growth
Published: 2022-09-02 (Crawled : 11:00) - prnewswire.com
NVS | News | $98.35 1.1% 0.0% 2.2M
|
Health Technology
|
| O: 0.21%
H: 0.86%
C: -0.99%
JNJ | News | $148.53 -0.69% -0.14% 9.6M
|
Health Technology
|
| O: 2.55%
H: 0.0%
C: 0.0%
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
|
| O: 0.32%
H: 0.04%
C: -2.83%
ABBV | News | $167.8 -1.03% -0.06% 4.1M
|
Health Technology
|
| O: 0.15%
H: 0.53%
C: -1.72%
dementia global report alzheimer's expected therapeutics growth market
Global Alzheimer's Disease Treatment Markets, Analysis & Forecasts, 2016-2021, 2021-2026F, 2031F: Focus on Cholinergic, Memantine, Combined Drug, AChE inhibitors, Immunoglobulins
Published: 2022-06-02 (Crawled : 10:00) - prnewswire.com
NVSEF | News | $96.0 6.88% 52K
|
Health Technology
|
| O: -0.31%
H: 0.0%
C: 0.0%
TAK | News | $13.23 -1.12% 0.0% 920K
|
Health Technology
|
| O: -3.16%
H: 0.36%
C: -0.07%
NVS | News | $98.35 1.1% 0.0% 2.2M
|
Health Technology
|
| O: -0.73%
H: 0.12%
C: 0.1%
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
|
| O: -0.9%
H: 0.0%
C: 0.0%
BMY | $48.86 -0.27% -0.02% 16M
|
Health Technology
|
| O: 0.21%
H: 0.0%
C: 0.0%
ABBV | News | $167.8 -1.03% -0.06% 4.1M
|
Health Technology
|
| O: -1.0%
H: 0.0%
C: 0.0%
treatment disease alzheimer's alzheimer’s
Quanterix Announces New Agreements with Lilly to Advance Alzheimer’s Disease Diagnosis and Treatment
Published: 2022-03-01 (Crawled : 13:00) - biospace.com/
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
|
| O: 1.26%
H: 0.0%
C: 0.0%
QTRX | $16.06 -0.25% -0.25% 350K
|
Health Technology
|
| O: 3.95%
H: 6.39%
C: -6.56%
alzheimer treatment new agreements disease alzheimer’s alzheimer's disease alzheimer's diagnostic
Eli Lilly’s Two-Year Ambition Includes Alzheimer’s Approvals
Published: 2021-12-15 (Crawled : 19:00) - biospace.com/
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
|
| O: 4.7%
H: 0.0%
C: 0.0%
alzheimer als approval alzheimer’s alzheimer's
Marking One Year Milestone, ADDI Expands Access to Global Data for Alzheimer's Researchers
Published: 2021-11-17 (Crawled : 12:00) - biospace.com/
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
|
| O: -0.49%
H: 0.0%
C: 0.0%
alzheimer research alzheimer’s milestone alzheimer's
Quanterix’ Simoa® Technology Powers Advances in Alzheimer’s Disease Research Presented at 2021 Clinical Trials on Alzheimer’s Disease (CTAD) Conference
Published: 2021-11-16 (Crawled : 15:30) - biospace.com/
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
|
| O: -0.26%
H: 0.0%
C: 0.0%
QTRX | $16.06 -0.25% -0.25% 350K
|
Health Technology
|
| O: -0.84%
H: 0.0%
C: -1.52%
disease alzheimer clinical trials trials technology research trial conference alzheimer’s alzheimer's disease alzheimer's
AC Immune Announces First Positive Cognitive Results for a Tau-Targeting Monoclonal Antibody in Alzheimer’s Disease
Published: 2021-08-31 (Crawled : 12:00) - globenewswire.com
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
|
| O: 0.2%
H: 0.3%
C: -1.73%
ACIU | $2.33 -2.1% -2.15% 320K
|
Health Technology
|
| O: 71.82%
H: 5.0%
C: -32.31%
disease alzheimer positive results antibody semorinemab alzheimer’s alzheimer's disease alzheimer's
Quanterix Simoa® Technology Powers Breakthrough Alzheimer’s Disease Research Presented by Eli Lilly and Company at Alzheimer’s Association International Conference (AAIC) 2021
Published: 2021-08-06 (Crawled : 13:00) - biospace.com/
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
|
| O: -0.18%
H: 0.0%
C: 0.0%
QTRX | $16.06 -0.25% -0.25% 350K
|
Health Technology
|
| O: -2.26%
H: 2.64%
C: -5.91%
disease alzheimer technology research conference alzheimer’s alzheimer's disease alzheimer's
Lilly and Banner Alzheimer's Institute collaborate on planned Phase 3 prevention trial of donanemab
Published: 2021-07-15 (Crawled : 14:15) - biospace.com/
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
|
| O: -0.57%
H: 0.42%
C: -1.51%
alzheimer phase 3 trial collaboration alzheimer’s alzheimer's
Lilly's donanemab receives U.S. FDA's Breakthrough Therapy designation for treatment of Alzheimer's disease
Published: 2021-06-24 (Crawled : 11:00) - prnewswire.com
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
|
| O: 8.21%
H: 1.89%
C: -0.83%
disease alzheimer treatment fda therapy breakthrough therapy alzheimer’s alzheimer's disease alzheimer's designation
Biogen’s Anuhelm Win Has Potential to Reinvigorate Alzheimer’s Investment
Published: 2021-06-08 (Crawled : 16:00) - biospace.com/
JNJ | News | $148.53 -0.69% -0.14% 9.6M
|
Health Technology
|
| O: 0.27%
H: 0.23%
C: -1.14%
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
|
| O: -0.36%
H: 0.25%
C: -0.46%
alzheimer potential alzheimer’s alzheimer's
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.